Investigating how SIN3a affects a key receptor in pulmonary arterial hypertension
Official title: Role of SIN3a in the epigenetic regulation of the Bone Morphogenetic Protein Receptor Type 2 in pulmonary arterial hypertension
Funded at New York Medical College · NIH-10914794 · Data updated 2026-11-12
This study is looking at how a protein called SIN3a affects another protein, BMPR2, which is important for keeping your lung blood vessels healthy, and it hopes to find new ways to help people with pulmonary arterial hypertension (PAH) by understanding how these proteins work together.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Medical College NIH-funded |
| Lab location | 1 site (Valhalla, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $135,303 |
| NIH project number | 5K01HL159038-03 |
| Project ID | NIH-10914794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension or those at risk for developing this condition.
✕Less likely to help
Patients with pulmonary arterial hypertension caused by factors unrelated to BMPR2 or SIN3a may not benefit from this research.
What this research studies
This research focuses on understanding the role of SIN3a in regulating the Bone Morphogenetic Protein Receptor Type 2 (BMPR2), which is crucial for maintaining healthy blood vessels in the lungs. By exploring the molecular mechanisms that lead to changes in BMPR2 expression, the study aims to uncover how these changes contribute to pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the lungs. The research involves examining the epigenetic modifications that affect BMPR2 in pulmonary artery endothelial cells, which may provide insights into potential therapeutic targets for PAH. Patients may benefit from a better understanding of the disease mechanisms, potentially leading to new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating pulmonary arterial hypertension.
How similar studies have gone: Previous studies have shown promising results in understanding the role of epigenetic factors in vascular diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
New York Medical College
Valhalla, United States Active
Researchers
- Principal investigator: Bisserier, Malik — New York Medical College
- Study coordinator: Bisserier, Malik
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.